Stage I–II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy

Michael S. Binkleya Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USACorrespondence[email protected]

Susan M. Hinikera Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA

Sheren Younesb Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

Christopher Yooa Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA

Anjali Wignarajahb Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

Michael Jina Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA

H. Henry Guoc Department of Nuclear Medicine, Stanford University School of Medicine, Stanford, CA, USA

Neel K. Guptad Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA

Yasodha Natkunamb Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

Ranjana H. Advanid Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA

Richard T. Hoppea Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA

Your download is now in progress and you may close this window